tbuckley/cabot-search huggingface dataset:
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) as early imaging biomarker of axillary sentinel lymph node (SLN) status in locally advanced node-positive breast cancer (NPBC) patients (pts) receiving neoadjuvant chemotherapy (NACT).
Authors: Yanina Dockx, Manon Thirza Huizing, Tim Van Den Wyngaert, Sevilay Altintas, Ivan Huyghe, Inge Geboers, Johan Vervliet, Christoph Molderez, Mireille van Goethem, Veerle van Marck, Hetty Sonnemans, Wiebren Tjalma
Journal: Journal of Clinical Oncology (2012)

1129 Background: Use of FDG-PET in the early evaluation of NACT for NPBC is currently under investigation. The aim of this study is to assess FDG-PET in NPBC pts receiving NACT in order to identify a subset of pts that can be spared axillary lymph node dissection (ALND) in case of response. Methods: All pts (period 2009-2011) had [cT2 (≥3cm)-T4, pN1-3], and no prior BC treatment. All pts received 8 cycles (cy) of NACT +/- trastuzumab. FDG-PET was performed at baseline and after 2 cy. After NACT, mastectomy with SLN and ALND was peformed. As primary endpoint, the change in maximum standardized uptake value (SUV max ) in the primary tumor (PT) and ALNs was compared with pathological response (Jonckheere-Terpstra test). Logistic regression was used to determine the predictive value of a 50% reduction in SUV max on pathological response and SLN status. Results: Forty-one pts were evaluable for the primary endpoint and 31 pts had successful SN procedures. The median age was 49.8 years (range 27-75). Overall, 9.8% (4/41; 95% CI 2.7 – 23.1) of pts had progressive disease (PD), 7.3% (3/41 ; 95% CI 1.5 – 19.9 ) stable disease (SD), 53.7% (22/41; 95% CI 37.4 – 69.3) partial response (PR), and 21.9% (9/41; 95% CI 10.6 – 37.6) a complete pathological response (pCR). A linear trend existed between pCR and higher decreases in SUV max of the PT site (p=0.008), but not with lymph node SUV max (p=0.294). The odds of achieving a pCR, increased significantly when SUV max of the PT decreased with &gt;50% (OR 10.7; 95% CI 1.2 - 98.0; p=0.03), but not lymph node SUV max (OR 4.75; 95% CI 0.82 - 27.5; p=0.08). Achieving a true negative SLN status was more likely with &gt;50% reductions in PT SUV max (OR 41.2; 95% CI 4.0 - 421.9; p= 0.002). A reduction of &gt;50% in nodal SUV max was not predictive of negative SLN status (OR 3.33; 95% CI 0.66 - 16.8; p=0.1). Conclusions: Early changes in PT metabolism imaged with FDG-PET after only 2 cy of NACT is a promising biomarker in the management of the axilla in NPBC. Molecular imaging of PT biology and to a lesser extent of axillary lymph nodes using FDG-PET warrants further study.
Hodgkin lymphoma staging 50 years later: no more knives or needles!
Authors: A. Gallamini
Journal: Annals of Oncology (2018)

In this issue, Voltin et al. report the results of a study aimed at assessing the value of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) and trephine bone marrow biopsy (BMB) in detecting bone or bone marrow invasion (BMI) by Hodgkin lymphoma (HL) in a cohort of 832 out of the 4153 patients prospectively enrolled in the HD16, HD17 and HD18 trials on behalf of the German Hodgkin Lymphoma Study Group [1].
The costs and benefits of replication studies
Authors: Nicholas A. Coles, Leonid Tiokhin, Anne M. Scheel, Peder M. Isager, Daniël Lakens
Journal: Behavioral and Brain Sciences (2018)

Abstract The debate about whether replication studies should become mainstream is essentially driven by disagreements about their costs and benefits and the best ways to allocate limited resources. Determining when replications are worthwhile requires quantifying their expected utility. We argue that a formalized framework for such evaluations can be useful for both individual decision-making and collective discussions about replication.
Serine Synthesis via PHGDH Is Essential for Heme Production in Endothelial Cells
Authors: Saar Vandekeere, Charlotte Dubois, Joanna Kalucka, Mark R. Sullivan, Melissa García-Caballero, Jermaine Goveia, Rongyuan Chen, Frances F. Diehl, Libat Bar-Lev, Joris Souffreau, Andreas Pircher, Saran Kumar, Stefan Vinckier, Yoshio Hirabayashi, Shigeki Furuya, Luc Schoonjans, Guy Eelen, Bart Ghesquière, Eli Keshet, Xuri Li, Matthew G. Vander Heiden, Mieke Dewerchin, Peter Carmeliet
Journal: Cell Metabolism (2018)
Annals Story Slam - Clerks, Codes, and Culture, or “We Weren't Even Supposed to Be Here!”
Authors: Richard M. Wardrop III
Journal: Annals of Internal Medicine (2018)

Web Exclusives17 July 2018Annals Story Slam - Clerks, Codes, and Culture, or “We Weren't Even Supposed to Be Here!”FREERichard M. Wardrop III, MD, PhDRichard M. Wardrop III, MD, PhDUniversity of North Carolina School of Medicine, Chapel Hill, North Carolina (R.M.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W18-0024 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Clerks, Codes, and Culture, or "We Weren't Even Supposed to Be Here!" "Clerks, Codes, and Culture, or 'We Weren’t Even Supposed to Be Here!'," by Richard M. Wardrop III (Duration 6:28)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: University of North Carolina School of Medicine, Chapel Hill, North Carolina (R.M.W.)Corresponding Author: Richard M. Wardrop III, MD, PhD; e-mail, [email protected]unc.edu. Previousarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 July 2018Volume 169, Issue 2Page: SS1 ePublished: 17 July 2018 Issue Published: 17 July 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.Loading ...
The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment
Authors: Bimal Bhindi, R. Houston Thompson, Christine M. Lohse, Ross J. Mason, Igor Frank, Brian A. Costello, Aaron M. Potretzke, Robert P. Hartman, Theodora A. Potretzke, Stephen A. Boorjian, John C. Cheville, Bradley C. Leibovich
Journal: European Urology (2018)
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
Authors: Véronique Diéras, Hope S Rugo, Patrick Schnell, Karen Gelmon, Massimo Cristofanilli, Sherene Loi, Marco Colleoni, Dongrui R Lu, Ave Mori, Eric Gauthier, Cynthia Huang Bartlett, Dennis J Slamon, Nicholas C Turner, Richard S Finn
Journal: JNCI Journal of the National Cancer Institute (2018)

Palbociclib administered with endocrine therapy was tolerable when the overall incidence of toxicities was assessed separately for three PALOMA studies. This study analyzed pooled, longer-term PALOMA safety data longitudinally.Data were pooled from three randomized phase II and III studies (ClinicalTrials.gov: NCT00721409, NCT01740427, NCT01942135) of hormone receptor-positive/human epidermal growth factor receptor 2‒negative advanced breast cancer patients. Front-line patients were randomly assigned to receive letrozole with/without palbociclib (PALOMA-1) or letrozole plus palbociclib/placebo (PALOMA-2). In PALOMA-3, patients with prior endocrine resistance received fulvestrant plus palbociclib/placebo. The cumulative event rates of adverse events (AEs), reporting up to 50 months of treatment, were assessed over time.Patients who received endocrine therapy (n = 1343) were included in this pooled analysis (872 were also treated with palbociclib, and 471 were not). The most common AEs with palbociclib plus endocrine therapy were neutropenia and infections (any grade, 80.6% and 54.7%, respectively), which were higher than in the endocrine monotherapy arm (any grade, 5.3% and 36.9%). The most common hematologic AEs (≥15.0% in the palbociclib arm) were more likely to be reported in the initial months of the study, after which time the cumulative event rate did not substantially increase. With palbociclib plus endocrine therapy, any grade AEs leading to permanent discontinuation over three years occurred in only 8.3% of patients.Based on these long-term safety analyses, there is no evidence of specific cumulative or delayed toxicities with palbociclib plus endocrine therapy, supporting the ongoing investigation of palbociclib plus endocrine therapy in early breast cancer (NCT02513394).
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
Authors: Emel Aygören-Pürsün, Anette Bygum, Vesna Grivcheva-Panovska, Markus Magerl, Jochen Graff, Urs C. Steiner, Olivier Fain, Aarnoud Huissoon, Tamar Kinaciyan, Henriette Farkas, Ramon Lleonart, Hilary J. Longhurst, William Rae, Massimo Triggiani, Werner Aberer, Mauro Cancian, Andrea Zanichelli, William B. Smith, Maria L. Baeza, Aurelie Du-Thanh, Mark Gompels, Teresa Gonzalez-Quevedo, Jens Greve, Mar Guilarte, Constance Katelaris, Sylvia Dobo, Melanie Cornpropst, Desiree Clemons, Lei Fang, Phil Collis, William Sheridan, Marcus Maurer, Marco Cicardi
Journal: New England Journal of Medicine (2018)

Hereditary angioedema is a life-threatening illness caused by mutations in the gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of the kallikrein-bradykinin cascade. BCX7353 is a potent oral small-molecule inhibitor of plasma kallikrein with a pharmacokinetic and pharmacodynamic profile that may help prevent angioedema attacks.In this international, three-part, dose-ranging, placebo-controlled trial, we evaluated four doses of BCX7353 (62.5 mg, 125 mg, 250 mg, and 350 mg once daily) for the prevention of angioedema attacks over a 28-day period. Patients with type I or II hereditary angioedema with a history of at least two angioedema attacks per month were randomly assigned to BCX7353 or placebo. The primary efficacy end point was the number of confirmed angioedema attacks. Key secondary end points included angioedema attacks according to anatomical location and quality of life.A total of 77 patients underwent randomization, 75 received BCX7353 or placebo, and 72 completed the trial. The rate of confirmed angioedema attacks was significantly lower among patients who received BCX7353 at daily doses of 125 mg or more than among those who received placebo, with a 73.8% difference at 125 mg (P<0.001). Significant benefits with respect to quality-of-life scores were observed in the 125-mg and 250-mg dose groups (P<0.05). Gastrointestinal adverse events, predominantly of grade 1, were the most commonly reported adverse events, particularly in the two highest BCX7353 dose groups.Once-daily oral administration of BCX7353 at a dose of 125 mg or more resulted in a significantly lower rate of attacks of hereditary angioedema than placebo. Mild gastrointestinal symptoms were the principal side effect. (Funded by BioCryst Pharmaceuticals; APeX-1 ClinicalTrials.gov number, NCT02870972 .).
Performance of Dermatology Physician Assistants
Authors: Ashfaq A. Marghoob, Michael A. Marchetti, Stephen W. Dusza
Journal: JAMA Dermatology (2018)

To the Editor In a recent issue of JAMA Dermatology, Anderson et al1 aimed to compare skin cancer diagnostic accuracy of physician assistants (PAs) with that of dermatologists (MDs) and used the number needed to biopsy as the main outcome measure.
Outcome in Dilated Cardiomyopathy Related to the Extent, Location, and Pattern of Late Gadolinium Enhancement
Authors: Brian P. Halliday, A. John Baksi, Ankur Gulati, Aamir Ali, Simon Newsome, Cemil Izgi, Monika Arzanauskaite, Amrit Lota, Upasana Tayal, Vassilios S. Vassiliou, John Gregson, Francisco Alpendurada, Michael P. Frenneaux, Stuart A. Cook, John G.F. Cleland, Dudley J. Pennell, Sanjay K. Prasad
Journal: JACC. Cardiovascular imaging (2018)

This study sought to investigate the association between the extent, location, and pattern of late gadolinium enhancement (LGE) and outcome in a large dilated cardiomyopathy (DCM) cohort. The relationship between LGE and prognosis in DCM is incompletely understood. The authors examined the association between LGE and all-cause mortality and a sudden cardiac death (SCD) composite based on the extent, location, and pattern of LGE in DCM. Of 874 patients (588 men, median age 52 years) followed for a median of 4.9 years, 300 (34.3%) had nonischemic LGE. Estimated adjusted hazard ratios for patients with an LGE extent of 0 to 2.55%, 2.55% to 5.10%, and >5.10%, respectively, were 1.59 (95% confidence interval [CI]: 0.99 to 2.55), 1.56 (95% CI: 0.96 to 2.54), and 2.31 (95% CI: 1.50 to 3.55) for all-cause mortality, and 2.79 (95% CI: 1.42 to 5.49), 3.86 (95% CI: 2.09 to 7.13), and 4.87 (95% CI: 2.78 to 8.53) for the SCD endpoint. There was a marked nonlinear relationship between LGE extent and outcome such that even small amounts of LGE predicted a substantial increase in risk. The presence of septal LGE was associated with increased mortality, but SCD was most associated with the combined presence of septal and free-wall LGE. Predictive models using LGE presence and location were superior to models based on LGE extent or pattern. In DCM, the presence of septal LGE is associated with a large increase in the risk of death and SCD events, even when the extent is small. SCD risk is greatest with concomitant septal and free-wall LGE. The incremental value of LGE extent beyond small amounts and LGE pattern is limited.
Myofibroblasts Induce Ectopic Activity in Cardiac Tissue
Authors: MicheleMiragoli, NicolòSalvarani, StephanRohr
Journal: Circulation Research (2007)

Focal ectopic activity in cardiac tissue is a key factor in the initiation and perpetuation of tachyarrhythmias. Because myofibroblasts as present in fibrotic remodeled myocardia and infarct scars depolarize cardiomyocytes by heterocellular electrotonic interactions via gap junctions in vitro, we investigated using strands of cultured ventricular cardiomyocytes coated with myofibroblasts, whether this interaction might give rise to depolarization-induced abnormal automaticity. Whereas uncoated cardiomyocyte strands were invariably quiescent, myofibroblasts induced synchronized spontaneous activity in a density dependent manner. Activations appeared at spatial myofibroblast densities >15.7% and involved more than 80% of the preparations at myofibroblast densities of 50%. Spontaneous activity was based on depolarization-induced automaticity as evidenced by: (1) suppression of activity by the sarcolemmal KATP channel opener P-1075; (2) induction of activity in current-clamped single cardiomyocytes undergoing...
Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes
Authors: Hai Dang Nguyen, Wan Yee Leong, Weiling Li, Pavankumar N.G. Reddy, Jack D. Sullivan, Matthew J. Walter, Lee Zou, Timothy A. Graubert
Journal: Cancer Research (2018)

Heterozygous somatic mutations in spliceosome genes (U2AF1, SF3B1, ZRSR2, or SRSF2) occur in >50% of patients with myelodysplastic syndrome (MDS). These mutations occur early in disease development, suggesting that they contribute to MDS pathogenesis and may represent a unique genetic vulnerability for targeted therapy. Here, we show that RNA splicing perturbation by expression of the U2AF1(S34F) mutant causes accumulation of R loops, a transcription intermediate containing RNA:DNA hybrids and displaced single-stranded DNA, and elicits an ATR response. ATR inhibitors (ATRi) induced DNA damage and cell death in U2AF1(S34F)-expressing cells, and these effects of ATRi were enhanced by splicing modulating compounds. Moreover, ATRi-induced DNA damage was suppressed by overexpression of RNaseH1, an enzyme that specifically removes the RNA in RNA:DNA hybrids, suggesting that the ATRi sensitivity of U2AF1(S34F)-expressing cells arises from R loops. Taken together, our results demonstrate that ATR may represent a novel therapeutic target in patients with MDS carrying the U2AF1(S34F) mutation and potentially other malignancies harboring spliceosome mutations.Significance: This study provides preclinical evidence that patients with MDS or other myeloid malignancies driven by spliceosome mutations may benefit from ATR inhibition to exploit the R loop-associated vulnerability induced by perturbations in splicing. Cancer Res; 78(18); 5363-74. ©2018 AACR.
Presence of pldA and exoU in mucoid Pseudomonas aeruginosa is associated with high risk of exacerbations in non–cystic fibrosis bronchiectasis patients
Authors: R.-G. Luo, X.-Y. Miao, L.-L. Luo, B. Mao, F.-Y. Yu, J.-F. Xu
Journal: Clinical Microbiology and Infection (2018)
Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal
Authors: Van K. Morris, Cathy Eng
Journal: Journal of the National Comprehensive Cancer Network (2018)

Anal cancer is a rare malignancy for which cisplatin with 5-fluorouracil is the recommended treatment for patients with metastatic disease. Because most cases of anal cancer are linked to prior infection with oncogenic strands of the human papillomavirus, immunotherapeutic approaches have been of great interest in the development of new treatments for this virally driven tumor. This article reviews the early successes of anti–PD-1 therapies and adoptive T-cell therapies for metastatic anal cancer as a potential foundation for novel combination immunotherapy trials in the future.
Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis
Authors: Thaís Armangue, Marianna Spatola, Alexandru Vlagea, Simone Mattozzi, Marc Cárceles-Cordon, Eloy Martinez-Heras, Sara Llufriu, Jordi Muchart, María Elena Erro, Laura Abraira, German Moris, Luis Monros-Giménez, Íñigo Corral-Corral, Carmen Montejo, Manuel Toledo, Luis Bataller, Gabriela Secondi, Helena Ariño, Eugenia Martínez-Hernández, Manel Juan, Maria Angeles Marcos, Laia Alsina, Albert Saiz, Myrna R Rosenfeld, Francesc Graus, Josep Dalmau, Sergio Aguilera-Albesa, Alfonso Amado-Puentes, Antonio Arjona-Padillo, Luisa Arrabal, Izascun Arratibel, Gemma Aznar-Laín, Paula Bellas-Lamas, Teresa Bermejo, Sabas Boyero-Durán, Ana Camacho, Andrea Campo, Dulce Campos, Verónica Cantarín-Extremera, Cristóbal Carnero, David Conejo-Moreno, Marta Dapena, David Dacruz-Álvarez, Verónica Delgadillo-Chilavert, Angela Deyà, Jordi Estela-Herrero, Anna Felipe, Elisa Fernández-Cooke, Joaquín Fernández-Ramos, Claudia Fortuny, Juan C García-Monco, Teresa Gili, Verónica González-Álvarez, Robert Guerri, Sara Guillén, Antonio Hedrera-Fernández, María López, Eduardo López-Laso, María Lorenzo-Ruiz, Marcos Madruga, Ignacio Málaga-Diéguez, Itxaso Martí-Carrera, Xavier Martínez-Lacasa, Lucía Martín-Viota, Leticia Martín Gil, María-Jesús Martínez-González, Antia Moreira, María C Miranda-Herrero, Lorena Monge, Beatriz Muñoz-Cabello, Juan Navarro-Morón, Olaf Neth, Antoni Noguera-Julian, Noemí Nuñez-Enamorado, Virginia Pomar, Juan C Portillo-Cuenca, María Poyato, Luis Prieto, Luis Querol, Eloy Rodríguez-Rodríguez, Silvana Sarria-Estrada, Concepción Sierra, Pere Soler-Palacín, Víctor Soto-Insuga, Laura Toledo-Bravo, Miguel Tomás, Carmen Torres-Torres, Eulàlia Turón, Ana Zabalza
Journal: The Lancet Neurology (2018)
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study
Authors: Benjamin R Bavinton, Angie N Pinto, Nittaya Phanuphak, Beatriz Grinsztejn, Garrett P Prestage, Iryna B Zablotska-Manos, Fengyi Jin, Christopher K Fairley, Richard Moore, Norman Roth, Mark Bloch, Catherine Pell, Anna M McNulty, David Baker, Jennifer Hoy, Ban Kiem Tee, David J Templeton, David A Cooper, Sean Emery, Anthony Kelleher, Andrew E Grulich, Andrew E Grulich, Iryna B Zablotska-Manos, Garrett P Prestage, Fengyi Jin, Benjamin R Bavinton, Beatriz Grinsztejn, Nittaya Phanuphak, David A Cooper, Anthony Kelleher, Sean Emery, Christopher K Fairley, David Wilson, Kersten K Koelsch, Kathy Triffitt, Nicolas Doong, David Baker, Mark Bloch, David J Templeton, Anna McNulty, Catherine Pell, Jennifer Hoy, Ban Kiem Tee, Richard Moore, Norman Roth, David Orth, Angie N Pinto
Journal: The Lancet HIV (2018)
HIV/AIDS: complacency risks reversing progress on ending epidemic, conference hears
Authors: Richard Hurley
Journal: BMJ (2018)

Complacency about HIV/AIDS and reduced funding risk rolling back advances towards ending the global epidemic, an international conference in Amsterdam has heard.

Last year almost a million people worldwide died from conditions related to AIDS and, of the 37 million infected with HIV, only 22 million have access to treatment.

“Too many people don’t get care,” the World Health Organization’s chief, Tedros Adhanom Ghebreyesus, told the AIDS 2018 conference. “We will not meet our targets,” he warned, calling for universal health coverage to include HIV prevention, diagnosis, and treatment.

“We must fight discrimination,” he said, listing populations at particular risk of HIV infection that lack access to effective healthcare because of stigmatisation and criminalisation: men who have sex with men, sex workers, injecting drug users, prisoners, transgender people, migrants, and refugees. “It’s unacceptable,” he said.

The …
A tissue-engineered scale model of the heart ventricle
Authors: Luke A. MacQueen, Sean P. Sheehy, Christophe O. Chantre, John F. Zimmerman, Francesco S. Pasqualini, Xujie Liu, Josue A. Goss, Patrick H. Campbell, Grant M. Gonzalez, Sung-Jin Park, Andrew K. Capulli, John P. Ferrier, T. Fettah Kosar, L. Mahadevan, William T. Pu, Kevin Kit Parker
Journal: Nature Biomedical Engineering (2018)
Neoadjuvant chemotherapy in locally advanced breast cancer.
Authors: Sami sahnoun Soraya
Journal: Journal of Clinical Oncology (2012)

e11034 Background: Neoadjuvant chemotherapy(NAC)is one of the treatment options for locally advanced breast cancer. In this study, we evaluated the efficacy and safety of 4 cycles of NAC doxorubicine,docetaxel and cyclophosphamide(TAC),correlation between the response to NAC and molecular classification sub-groups and between the pCR and the time to progression(TTP). Methods: This is a prospective study from January 2005 to December 2008.110 pts with locally advanced breast cancer stage III.All pts have received 4 cycles of NAC based on docetaxel 75 mg/m², doxorubicine 50 mg/m² and cyclophosphamide 500 mg/m² every 3 weeks, followed by surgery.101 pts were assessed, since 9 of them have progressed on treatment and came out of the study. Pts were stratified according to age, menopausal status, histopathological analysis (luminal tumors(ER-positive and HER2-negative), triple-negative tumors (TN)and HER2-positive tumors), response to the treatment and survival. The median follow up of patients was 39 months. The statistical study was done using SPSS 17. Results: The median age was 41(23–65).30% of pts were younger than 35 and 80% were premenopausal. 55% luminal tumors(56 pts), 33% HER2 positive(33 pts) and 12 % TN(12 pts).CRR was estimated at 89%(37% of CR and 63% of PR).There were 23, 7% of pCR according to Chevallier’s classification. In luminal, TN and HER2-positive pCR rates were 16%(9 of 56), 66,6%(8 of 12), and 21,2%(7 of 33) respectively. Multivariate analysis showed that the ER status was the only significant predictor of pCR(P = 0.025).HER2 status was not significantly associated with pCR(P= 0,423).TTP was 50 months. In luminal tumors, TN and HER2-positive tumors the TTP was respectively 59, 52 and 49 months. There was not a significant difference in TTP between the pCR(51 months) and the non-pCR group(44 months)(CI 95, p= 0.109).Grade III/IV toxicity included neutropenia(22%), febrile neutropenia(6,5%), mucositis(13%), and diarrhea(4%). Conclusions: Breast cancer occurs in young women in Algeria. In this study, neoadjuvant TAC was effective and well tolerated. The ER status was the only significant predictor of pCR. The molecular classification group with the highest percentage of pCR was the TN group. pCR was not associated with a better prognosis.